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today, there are only two kinds of people - the infected and
the affected. For this reason all South Africans have an
obligation to contribute to halting the spread of HIY, and to
providing care for the infected. To ensure that there is still a ~
viable and just health system in the future, all South Africans
will have to contribute to the management of HlV/ AIDS.
CONCLUSION
Although the government has spent the last 7 years
investigating the SHI and NHI options, it has not been able to
come to a decisive conclusion. The plausible reason is that the
country itself is not united under one option. This lack of
agreement among South Africans may explain the
government's paralysis on this matter. One can continue to
debate the different options. In the meantime, the cost on the
health of South Africans as demonstrated, for example, by the
exploding HlV/ AIDS epidemic, is immeasurable.
The author would like to thank Ms Efua Dorkenoo for editing
the document. The views expressed here remain those of the
author and are not necessarily those of the Human Sciences
Research Council. They were informed by the debates held on this
subject since 1994.
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CLINICAL VERSUS MOLECULAR
DIAGNOSIS OF HETEROZYGOUS
FAMILIAL HYPERCHOLESTEROL-
AEMIA IN THE DIVERSE SOUTH
AFRICAN POPULATION
Joseph Vergotine, Rochelle Thiart, Maritha J Kotze
Objective. Familial hypercholesterolaemia (FH) is a common
genetic disease characterised by strikingly elevated. plasma
cholesterol concentration, which can lead to premature
coronary death if left untreated. In this study DNA
diagnosis of FH, which allows detection before onset of
clinical symptoms, was evaluated against biochemical
parameters routinely used to identify subjects with FH.
Design. A population-based strategy was used to identify
low-density lipoprotein receptor (LDLR) gene defects in
South Africans with clinical signs of FH, followed by a
family-based DNA screening approach for presymptomatic
diagnosis of FH.
Results. DNA screening of 790 at-risk relatives for the FH-
related mutations identified in 379 index cases, allowed
accurate disease diagnosis in an additional 338 relatives and
exclusion of the relevant mutation in 452 individuals. The
sensitivity and speeifidty of the diagnosis, based on total
cholesterol values measured in family members of FH
heterozygous index cases with one of the three founder-
related mutations, D154N, D206E and V408M, were 89.3%
and 81.9%, respectively.
Conclusion. The predominance of 10 LDLR gene mutations
in the local population justifies population-directed D A
diagnosis of FH in South Africa on a routine basis,
particularly since expression of the defective gene measured
in biochemical tests does not allow accurate diagnosis of FH
in all cases. D A testing provides a definitive tool for
family tracing aimed at pre-clinical diagnosis and
preventive treatment of FH.
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The diagnosis of familial hypercholesterolaemia (PH) is based
on clinical findings and elevated low-density lipoprotein (LDL)
cholesterol levels. The rare homozygous form of the disease is
characterised by severe clinical features, including tendon
xanthomas and atherosclerosis, usually associated with early
coronary death during childhood. Most PH heterozygotes
carrying one defective low-density lipoprotein receptor (LDLR)
gene do not present with cholesterol deposits in the skin and
tend~ns,which complicates disease diagnosis and
consequently preventive treatment.1DNA analysis may
therefore be more appropriate for the diagnosis of
heterozygous PH, particularly in homogeneous populations
where a limited number of LDLR gene mutations account for
the disease in the majority of cases.
The diverse South African population provides a valuable
source of material for genetic studies. Initial studies of PH
patients focused on the Afrikaner population, considered to be
a genetic isolate because of its geographical and historical
situation. The predominance of specific haplotypes in this
population group2.3 confirmed the occurrence of a founder
effect: and led to the identification of three mutations that are
responsible for the disease in approximately 90% of Afrikaner
PH patients.s-7The value of a routinely used D A-based test
was demonstrated!,' necessitating the development of a c.ost-
effective method to screen for multiple mutations in a single
reaction.!O Population screening by direct detection of the
founder mutations Dl54N, D206E and V408M, confirmed the
high prevalence of heterozygous PH 0/70) in Afrikaners. 1I
Loubser et al.l'demonstrated that these mutations are also
responsible for the disease in 15 - 20% of South African PH
patients of mixed ancestry (coloured population). This finding,
as well as frequent detection of two LDLR gene mutations
causing PH in the majority of South African Jews (deI3-bp)13
and Indians (P664L),!'·15 provided direct genetic evidence that
Caucasoid admixture contributes significantly to the PH
phenotype in South Africans of mixed ancestry. A 6-bp deletion
identified in a Xhosa with homozygous PH16 appeared to be
absent in the coloured population.12 Frequent detection of this
deletion-mutation in PH patients from the South African black
population,!7 where this disease appears to be extrem.ely rare,
suggests that PH may be underdiagnosed in this group. This
finding supports the notion that clinical criteria for the
diagnosis of PH need to differ by country/ population. IS
D A screening for PH should be a priority in South Africa
where specific founder-type mutations contribute significantly
to the high death rate from coronary heart disease (CHD) in
several population groups. However, PH is largely
underdiagnosed locally, such that most affected individuals are
not treated to prevent unnecessary early deaths due to heart
attacks. Routine screening is ongoing to identify the disease-
causing mutation in patients referred for molecular diagnosis,
but family follow-up is rarely performed. This is an
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unfortunate situation, since tracing of defective LDLR genes in
families would facilitate accurate diagnosis of PH or exclusion
of the disease ill at-risk relatives. Most importantly, it would
identify those family members at high risk of developing CHD,
so that cholesterol levels can be lowered or normalised by
dietary and/or drug treatment.
In an attempt to identify and assist families with PH, an
international project aimed at Making Early Diagnosis to
Prevent Early Deaths in MEDical PEDigrees (MED-PED) was
initiated, which currently involves more than 30 countries
worldwide. In a report by Williams et aI. I ' on this family-based
case-finding approach, it was suggested that more rigid
cholesterol screening should be used for persons in the general
population whose chance before cholesterol testing may be
only 1 in 500 0 in 70 among Afrikaners), in contrast to first-
degree relatives of a confirmed PH case whose chance before
cholesterol testing is 50%. In this study the MED-PED approach
was followed to screen family members of molecularly
characterised PH index patients for known mutations in the
LDLR gene. In order to extend the spectrum of LDLR gene
mutations, clinically diagnosed PH index cases without known
mutations were subjected to extensive screening of the
promoter and coding region of the LDLR gene. The overall
objective of the study was to determine what percentage of
adult PH patients heterozygous for mutations DI54N, D206E
or V408M could be diagnosed accurately on the basis of raised
total cholesterol levels.
MATERIALS AND METHODS
Subjects
The initial study population consisted of hypercholesterol-
aemics referred for a molecular diagnosis of PH, based on
previously described criteria.'-' For this study, follow-up
mutation screening was performed/extended in families where
the PH-related mutation had been identified in the index case.
Index cases without known mutations were subjected to
extensive mutation screening followed by mutation screening
in relevant at-risk family members. In these index patients
pretreatment total serum cholesterol (TC) levels had to be at
least equal to the 90th percentile for age and gender,211 with
normal serum triglyceride (TG) levels
« 2.3 mmol/1). In addition, an PH study participant had to
have either clinical features of PH (tendon xanthoma of the
Achilles tendon or tendons on the dorsum of the hand with or
without xanthelasma) or a family history of early CHD. We
report on all the mutation-positive cases identified in this
study, together with mutation data described previously in
South African families (Table 1). Known mutations causing
familial defective apolipoprotein B-I00 (FDB) were excluded in
all the study participants using previously described
methods.21 .22
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Table I. Spectrum of mutations identified in the LDLR gene in different South African population groups
Exon/ Relatives
intron Molecular event Designation No. tested
Alrikiner population
Exon3 T-.fu at 259 W66G* 1 None
Exon4 G~Aat523 Dl54N 31 55 +, 105-
Exon4 A~G at 662 D200G 5 3 +, 1-
Exon4 Ins 18-bp after 681 Ins AA 201-206 1 1 +,5-
Exon4 C-.fu at 681 D206E 144 144 +, 194-
Exon6 C~Tat917 S28SL 3 2+,2-
Exon 7 C~Tatl048 R329X 1 None
Exon8 G~Aat1130 C356Y+ 4 5 +, 1-
Exon8 G~Tat1145 G361V+ 2 3 +,4-
Exon9 G~Aat128S V408M 57 51 +,61 -
Exon 16 G~Aat2389 V776M 1 None
Mixed ancestry (coloured population)
Promoter C~Tat-59 -59c~ t 1 3 +, 14-
Exon 1 T~C at 28 W-I2R 1 None
Exon2 G~Aatl48 A29T 1 None
Exon3 C~Tat232 RS7C 1 None
Exon3 C~Tat241 R60C 1 one
Exon4 del TC after 368 del2-bp 1 one
Exon4 G~Aat523 Dl54N 2 one
Exon4 Del GGT after 651 del3-bp 4 one
Exon4 A~at662 D200G 1 one
Exon4 A~Gat680 D203A 1 one
Exon4 C~at681 D206E 19 4 +,4-
Exon4 ~Aat682 E207K 1 one
Exon4 T~G at 691 C210G 1 one
Exon5 G~Aat772 E237K* 1 4 +, 7-
lntron 6 G~Aat941-4 941-4 G~A 1 one
lntron 6-8 deI2.5-kb del2.5-kb 10 2+
Exon8 T~atl154 L364R 1 one
Exon 9 G~Aat1285 V408M 13
Exon 14 C~Tat2054 P664L 3 one
Black population
Promoter del erc after -92 del3-bp 1 one
Exon2 del 6-bp after 138 del6-bp 4 1 +,2-
Exon2 del G at 172 dell-bp 1 one
lntron 3 G~Aat313+1 313+1G~A 1 4-
Exon4 G~Cat514 Dl51H 1 one
Exon5 C~Tat756 R232W 1 1 +,3-
Exon 9 G~Aat 1217 R38SQ 1 one
Exon 9 G--?A at 1222 E387K 1 5+,5-
Exon 14 C-.-?T at 2096 P678L 1 one
Exon 17 G-.-?Jl at 2441 R793Q 1 one
Indian population
Exon 1 A-.-?T at 1 M-21L 1 2 +, 1·-
Exon3 C-.-?T at 232 RS7C 1 one
Exon3 G-.-?T at 268 D69Y 1 one
Exon4 G-.-?A at 418 E119K 1 one
Exon4 G-.-?T at 661 D200Y 1 2 +,3- mm
Exon4 G-.-?A at 682 E207K 2 8 +, 7-
Exon 8 C-.-?A at 1175 C371X 1 11 +,9-
Exon 9 C--?G at 1215 384K 1 3 +, 2-
Exon 14 C-.-?T at 2054 P664L 10 one
Exon 16 A-.-?T at 2356 S76SC 1 4+,2-
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Table I. Continued
Jewish population
Exon3 C~Tat2S3 Q64X 2 1+
Exon4 C~Tat373 Q104X" 1 None
Exon4 del GGT after 651 del3-bp 5 1+
Exon4 C~at681 D206E 1 2-
lntron 9 G~A at 1358+1 1358+1 G~A" 1 None
Exon9 C~atl284 N407K" 1 2+
Exon9 G~Aatl28S V408M 1 None
Intron 14 G~A at 2140+5 214O+5G~A 1 None
European ancestry
Exon3 C~Tat232 R57C 1 None
Exon4 InsG at 558 558 ins G 1 1 +,3-
Exon4 delG at 617 617 del G 1 None
Exon4 C~at68P 0206E 1 None
Exon6 G~Aat910 0283N 1 . None
Exon7 C~Tatl048 R329X 1 None
Exon8 A~at1133 Q357P 1 None
Exon8 C~Tat1150 Q363X 1 3+,4-
Exon8 C~at1156 0365E 1 3+,4-
Exon9 G~at1329 W422C 1 None
Exon 10 Complex del!ins 16-bp dellS-bp inst 1 None
Exon 10 T~atl447 W462R 1 None
Exon 11 G~Aatl646 G528D 1 2+
Exon 11 A~atI690 N543H 1 None
Exon 14 C~Aat2043 C660X 2 7+,2-
Exon 14 del Tat2092 2092 del T 1 4+,1-
Intron 14 G~A at 2140+5 2140+5G~A 1 None
Exon 17 del 9-bp after 2393 2393 del 9-bp 1 None
• M Callis and R Thiart - unpublished data.
t Novel mutation identified in this study.
The majority of mutations summarised in this table are included in FH database; htW://www.umd.necker.fr. and htW:llwww.ucl.ac.uk/fh. Relatively common mutations that may
represent founder mutations are highlighted. The number of family membeIs who tested positive (+) or negative (-) for the mutation identified in the index case is indicated.
The study protocol was approved by the Ethics Review
Committee of the University of Stellenbosch and all blood
samples were obtained with informed consent. In this study
'White or Afrikaner' refers to an individual of European
descent, mainly Dutch, French, German and British origin;
'coloured' refers to an individual of mixed ancestry, including
San, KIwi, African Negro, Madagascar, Javanese and European
origin; and 'black' refers to South Africans of central African
descent.
DNA analysis
Genomic DNA was extracted from whole blood collected in
EDTA-<:ontaining tubes, according to a standard technique.23
Polymerase chain reaction (PCR) amplification of the LDLR
gene was performed using the exon-specific primers described
by Jensen et al.,z' or allele-specific primers specially designed
for detection of mutations known to be common in South
Africa. IO Heteroduplex single-strand conformation
polymorphism (HEX-SSCP) analysis lO was performed using
three different gel systems to improve mutation detection
efficiency: 10% polyacrylamide gel supplemented with 7.5%
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urea; 10% polyacrylamide gel supplemented with 5% glycerol
and 20% polyacrylamide gel. Electrophoresis was carried out
overnight at room temperature and at 4°C on a 20 cm Hoeffer
gel apparatus. When no aberrant patterns could be detected
using the HEX-SSCP method, denaturing gradient gel
electrophoresis (DGGE) was performed as described by Nissen
et aJ.22PCR products showing aberrant patterns were sequenced
with the automated AB! 373 system. Where appropriate,
restriction enzyme analysis was performed for confirmation, to
screen for known mutations, and to trace specific mutations in
families.
Clinical evaluation
Evaluation of biochemical versus DNA diagnosis was
performed in families with the Afrikaner founder mutations
0206E (PHI), V408M (FH2) or D154N (PH3), the deleterious
effects of which have previously been confirmed at the cellular
level.25,26 Since index patients had been selected on the basis of
elevated TC levels, genotype/phenotype correlation studies
were only performed on family members recruited through
tracing of defective genes in the pedigrees.
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RESULTS
The spectrum of mutations in the South African population,
including 65 different mutations identified in 379 index cases,
is summarised in Table I. Of the 790 at-risk relatives analysed,~
338 inherited the disease-related LDLR gene mutation. In
addition to the earlier reports on Afrikaners··· and Jews,"
detailed data have recently been published on families from
the coloured,12 black17 and Indian"·I' populations.
Segregation analysis of mutation S285L identified in an
Afrikaner family (Fig. 1) demonstrated that one of the
mutation-negative children (Il-3) had a TC concentration above
the 80th percentile (4.9 nunol/1), which might have been falsely
classified as heterozygous FH in the absence of the DNA test.
This finding was in accordance with previous data of Kotze et
al.v who demonstrated that a value of 6 mmolll might best
discriminate between mutation-positive and
-negative children within Afrikaner FH families.
In Table IT, 443 at-risk family members (above the age of 18
years) screened for one of the three Afrikaner founder
mutations (Dl54N, D206E or V408M) previously identified in
the index case, were grouped according to the presence of TC
levels above the 80th and 95th percentile for age and gender.
Evaluation of biochemical versus DNA diagnosis revealed that
Family no. 943
Mutation S285L
[J
1
11
2 3 4
Age 45 17 11 9 43
TC 8.4 4.7 6.9 4.9 7.1
HDL 1.2 1.6 1.1 1.6 1.8
TG 1.6 0.6 1.2 0.9 0.6
LDL 6.5 2.8 5.2 2.9 5.0
Fig. 1. Segregation analysis of mutation 5285L in an Afri,,?ner
family where one of the children (indic~ted by. a.n arrow) dIed at the
age of 6 years of a heart attack. MutatIOn-pOSItIve cases are mdlcat~
by dark-shaded symbols. (TC = total cholesterol; HDL = hlg!'-denslty
lipoprotein cholesterol; TG = triglyrmdes; LDL = low-denslty
lipoprotein cholesterol.)
15.6% of cases may be misdiagnosed when the 80th percentile
is used as a biochemical cut-off point for a diagnosis of FH,
compared with 12.4% using the 95th percentile'" for age and
gender. In total, 16/150 relatives 00.7%) with an FH mutation
were falsely classified as normal (negative predictive value of
89.3%), while 53/293 08.1%) without the mutation were falsely
classified as FH heterozygotes (positive predictive value of
81.9%). The sensitivity and specificity of FH diagnosis
according to TC values (80th percentile) were therefore 89.3%
and 81.9%, respectively.
DISCUSSION
The mutational spectrum underlying lipid abnormalities differs
among population groups. Knowledge of the spectrum of gene
defects causing primary hypercholesterolaemia in a specific
population and in affected families allows accurate disease
diagnosis and preventive treatment. The presence of at least 10
founder-type LDLR gene mutations in the South African
population (highlighted in Table I) enhances the prospects of
DNA-based diagnosis of FH in this country. After exclusion of
the three previously-described Afrikaner founder mutations,
D206E, V408M and Dl54N, a further eight mutations were
identified in this population group. Four of these mutations,
D200G, S285L, C356Y and G361V, detected in 14 Afrikaner
families, probably represent minor founder mutations of which
the associated haplotypes have been defined previously using
10 LDLR gene polymorphisms.>
The novel insertion/deletion mutation identified in exon 10
was absent in more than 100 normal chromosomes screened.
This complex mutation deletes 16 bases from nucleotide 1379
to 1394 (ACGGCGTCTCTTCCTA) and is replaced by five bases
(CAGCT); and six amino acids, His439-Gly440-Val441-SER442-
Ser443-Tyr444, were replaced by two amino acids, Pr0439-
Ala440. The insertion results in a stop cadon at amino acid
position 441 and is therefore highly likely to affect the LDLR
function and cause FH.
In the family with mutation S285L where both parents were
heterozygous for this mutation, one of the children died at the
age of 6 years of a heart attack. This event was most likely
caused by the inheritance of two copies of mutation S285L.
Since termination ot a pregnancy is justified in the case of an
Table n. Evaluation of biochemical versus DNA diagnosis in family members of A.frlkaner index patients (> 18 years) with disease-causing
LDLR gene mutations
Mutation
D206E
V408M
D154N
No mutation
Total
Number of relatives
93
27
30
293
443
> 95th percentile (%)
61 (66)
20 (74)
25 (83)
12 (4)
> BOth percentile (%)
82 (88)
23 (85)
29 (97)
53 (18)
FH homozygous fetus, a prenatal diagnosis of FH was recently
performed in an Afrikaner family with the founder mutation
D206E.28 The parents requested this procedure because they
already had one severely affected child shown to be
homozygous for this LDLR gene mutation. The DNA test
results indicated a normal fetus, which led to continuation of
the pregnancy. Since the risk of homozygous FH offspring is
extremely high (25%) in cases where both parents have
heterozygous FH, prenatal diagnosis of this condition is of
particular importance in the South African population with an
increased incidence of certain disease-related LDLR gene
mutations.
In this study the evaluation of biochemical versus DNA
diagnosis, previously performed in 220 children between the
ages of 2 and 18 yearsj7 was extended in an Afrikaner adult
group including 443 close relatives of 232 index patients with
one of the common founder mutations DI54N, D206E or
V408M. Although the majority of mutation-positive cases were
identified for the first time during mutation screening, the
relatively low sensitivity value of 89.3%, compared with 93% in
the sample of children, could be attributable to altered dietary
habits in FH families or influence of other external factors that
are more prevalent in adulthood (e.g. smoking, diabetes). The
specificity value also differed between the adult (81.9%) and
child (89%) samples, which demonstrated that TC levels as a
diagnostic means are more accurate in children than in adults.
DNA tests are therefore the preferred method for the diagnosis
ofFH.
Separate evaluation of the Afrikaner founder mutations
versus TC levels (> BOth percentile) suggests that the
penetrance of mutation DI54N is the highest of the three
Afrikaner founder mutations. The estimated sensitivity of
detecting this receptor-defective mutation" using biochemical
parameters was 97%, compared with 88% for mutation D206E
and 85% for mutation V408M. The finding that mutation
V408M, previously shown to result in less than 2% of receptor
activity (receptor-negative) is biochemically expressed to a
lesser or equal degree than mutations DI54N and D206E
(receptor-defective, 20% activity), may be due to the small
number of V408M-positive relatives analysed. Another
explanation for this phenomenon may, however, be related to
the finding that mutation DI54N occurs in as with mutation
A370T, representing a Stul polymorphism29 that may have a
subtle effect on plasma lipid levels.30
Interestingly, one of the male patients with mutation V408M
exhibited a normal TC value. This finding provides us with
another example of the extent of clinical variability in FH.31.J2
The normal TC value in this V408M heterozygote could be due
to interaction with a cholesterol-lowering gene.33-"Sass et al.35
hypothesised that the apo E2 allele of the apolipoprotein E
polymorphism may be a potent cholesterol-lowering factor.
The likelihood of apo E allelic status as a contributing factor
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has been excluded in the South African normocholesterolaemic
individual with mutation V408M, since this subject was
homozygous for the neutral E3 allele (J N P de Villiers -
unpublished data). The genetically homogeneous Afrikaner
population provides a valuable source of material for gene-
gene interaction studies and is increasingly used for this
purpose.36
Approximately half of the offspring of an affected parent can
be expected to have a severely elevated plasma cholesterol
level from birth onwards, as was demonstrated in the child27
and adult samples. Cardiovascular disease usually manifests in
patients with FH before the age of 55 years,' which appears to
correspond with data for the Afrikaner population.n•31 Notably,
none of the black FH patients shown to be heterozygous for a
6-bp deletion in exon 2 presented with CHD.17 Although none
of these subjects displayed variation in the LDLR promoter
region shown to be associated with altered phenotypic
expression of FH in African populations where these mutations
prevail,l7.37 other modifier genes and/or environmental factors
may be involved. It is tempting to speculate that the prevalence
of (clinical) FH is likely to increase with westernisation of the
black population, once the apparently aggravating effect of the
relatively common -175g ~t polymorphism" is manifested in
the presence of other causative FH mutations.
This study demonstrated that FH has a very high penetrance
in populations of European descent, which justifies a genetic
diagnosis of this treatable disease. The main advantage of DNA
diagnostics is its very high specificity compared with
biochemical parameters. The value of the family-based MED-
PED screening approach is that identification and treatment of
FH is assured early in life. It also provides the opportunity for
genetic counselling to inform families of the importance of
mutation screening in other relativeS. Extension of this
approach to the population at large would allow more FH
patients to be diagnosed and subsequently treated by their
clinicians, or referred to lipid clinics where they can receive the
intensive care their condition justifies.
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